Cardiovascular Health and Text Messaging-Diabetes Mellitus (CHAT-DM) Study

Coronary Artery Disease Clinical Trial

Official title:

Effectiveness of Text Messaging on Risk Factors Control and Medication Adherence Among Patients With Coronary Heart Disease and Diabetes in China: Cardiovascular Health and Text Messaging-Diabetes Mellitus (CHAT-DM) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02883842
• Other study ID #: 201502009-2
• Status: Completed
• Phase: N/A
• Start date: August 2016
• Est. completion date: November 2017

Study information

• Verified date: May 2018
• Source: China National Center for Cardiovascular Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a two-arm, parallel, randomized clinical trial. The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention, including lifestyles modification, medication adherence improvement and risk factors control among coronary heart disease (CHD) patients with diabetes. The participants will be randomized into intervention and control groups in a 1:1 ratio. The intervention group will receive 6 pre-designed text messages per week in addition to usual care for 6 months, while the control group will receive usual care.

Description:

Objective: This study aims to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention, including lifestyles modification, medication adherence improvement and risk factors control among CHD patients with diabetes. We hypothesized that an intervention using mobile phone text based education and reminder can improve risk factors control and medication adherence for CHD patients.

Study design: The study is a two-arm, parallel, randomized clinical trial. Patients will be eligible if they have documented CHD defined as having history of myocardial infarction and percutaneous coronary intervention (PCI), have a history of diabetes mellitus, have the capability of reading and sending short message, and are able to provide informed consent. Patients will be excluded if they do not have an active mobile phone. The eligible participants will be allocated into intervention and control groups in a 1:1 ratio randomly. The intervention group will receive intervention of pre-designed text messages in addition to usual care, while the control group will receive usual care. All the participants will be followed up for 6 months.

Study intervention: Participants in the intervention group will receive text messages for 6 months as well as usual care. They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.

Outcome measures: The primary endpoint is the change in glycemic hemoglobin (HbA1C) as measured by central blood sample. Secondary endpoints include a change in proportion of patients achieving HbA1C<7%, body mass index (BMI), physical activity, medication adherence, systolic blood pressure, low-density lipoprotein cholesterol (LDL-C) and fasting blood glucose (FBG). Exploratory endpoints include long-term prognosis of the patients, such as death, nonfatal myocardial infarction, stroke and so on, as well as health status (SAQ and EQ-5D).

Statistical analysis: Evaluation will be carried out on an intention-to-treat basis. Values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan. We'll follow a prespecified analysis plan and subgroup analysis will be conducted accordingly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 502
• Est. completion date: November 2017
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Participants with coronary artery disease defined as history of myocardial infarction and PCI

• History of diabetes

• Capability to read and send text messages

Exclusion Criteria:

• Assumed poor adherence

• Do not have an active mobile phone

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Diabetes
• Diabetes Mellitus
• Myocardial Ischemia

Intervention

Behavioral:
• Text messaging
Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.

Locations

Country	Name	City	State
China	Fuwai hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in glucose level measured by HbA1C level	We will measured the change in glucose level from baseline to 6 months.	Baseline; 6 months
Secondary	Change in proportion of patients achieving HbA1C<7%	We will measure the change in proportion of patients achieving HbA1C<7% from baseline to 6 months.	Baseline; 6 months
Secondary	Change in level of fasting blood glucose (FBG)	We will measure the change in FBG level from baseline to 6 months.	Baseline; 6 months
Secondary	Change in body mass index (BMI) according to national standards	We will measured the change in BMI from baseline to 6 months.	Baseline; 6 months
Secondary	Change in systolic blood pressure (SBP) obtained in office during each interview	We will measured the change in SBP from baseline to 6 months.	Baseline; 6 months
Secondary	Change in level of physical activity measured via International Physical Activity Questionnaire (IPAQ) scale	We will measure the change in IPAQ scale from baseline to 6 months.	Baseline; 6 months
Secondary	Change in medication adherence	We will measure the change in medication adherence from baseline to 6 months.	Baseline; 6 months
Secondary	Change in low-density lipoprotein cholesterol (LDL-C) level	We will measure the change in LDL-C level from baseline to 6 months.	Baseline; 6 months